Cargando…

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future

Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs. JAKi are c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angelini, Jacopo, Talotta, Rossella, Roncato, Rossana, Fornasier, Giulia, Barbiero, Giorgia, Dal Cin, Lisa, Brancati, Serena, Scaglione, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408575/ https://www.ncbi.nlm.nih.gov/pubmed/32635659 http://dx.doi.org/10.3390/biom10071002

Ejemplares similares

Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection?
por: Roncato, Rossana, et al.
Publicado: (2022)

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
por: Roncato, Rossana, et al.
Publicado: (2020)

Calcium physiology, metabolism and supplementation: a glance at patients with ankylosing spondylitis
por: Talotta, Rossella, et al.
Publicado: (2020)

Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
por: Talotta, Rossella, et al.
Publicado: (2018)

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
por: Taylor, Peter C
Publicado: (2019)

Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer?
por: Mehta, Puja, et al.
Publicado: (2020)

JAK/STAT pathway in pathology of rheumatoid arthritis (Review)
por: Ciobanu, Dana Alexandra, et al.
Publicado: (2020)

Clinical use of Jak 1 inhibitors for rheumatoid arthritis
por: Nash, Peter
Publicado: (2021)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses
por: Talotta, Rossella, et al.
Publicado: (2017)

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
por: Harigai, Masayoshi
Publicado: (2019)

Negative Regulators of JAK/STAT Signaling in Rheumatoid Arthritis and Osteoarthritis
por: Malemud, Charles J.
Publicado: (2017)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2013)

JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
por: Moura, Rita A., et al.
Publicado: (2021)

Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis
por: Wang, Faping, et al.
Publicado: (2022)

Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
por: Convertino, Irma, et al.
Publicado: (2023)

Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis
por: Pei, Heying, et al.
Publicado: (2018)

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
por: Harrington, Robert, et al.
Publicado: (2020)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

Targeted therapies in rheumatoid arthritis: Focus on rituximab
por: Teng, YKO, et al.
Publicado: (2007)

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
por: Kay, Jonathan, et al.
Publicado: (2020)

Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Emery, Paul, et al.
Publicado: (2018)

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
por: Fragoulis, George E, et al.
Publicado: (2019)

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
por: Kotyla, Przemysław J., et al.
Publicado: (2020)

Joint Location–Specific JAK‐STAT Signaling in Rheumatoid Arthritis Fibroblast‐like Synoviocytes
por: Hammaker, Deepa, et al.
Publicado: (2019)

Pulmonary nodules associated with JAK inhibitor therapy in rheumatoid arthritis: A case report
por: Pannell, N, et al.
Publicado: (2021)

Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis
por: Zhang, Ning, et al.
Publicado: (2021)

Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity
por: Ptacek, Jason, et al.
Publicado: (2021)

Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study
por: Venerito, Vincenzo, et al.
Publicado: (2023)

Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
por: Yilmaz, Sedat, et al.
Publicado: (2013)

Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies
por: Senolt, Ladislav
Publicado: (2019)

Role of Infections in the Pathogenesis of Rheumatoid Arthritis: Focus on Mycobacteria
por: Bo, Marco, et al.
Publicado: (2020)

The Role of Cell Organelles in Rheumatoid Arthritis with Focus on Exosomes
por: Payandeh, Zahra, et al.
Publicado: (2021)

Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment
por: Wu, Di, et al.
Publicado: (2022)

Design of novel JAK3 Inhibitors towards Rheumatoid Arthritis using molecular docking analysis
por: Jain, Divya, et al.
Publicado: (2019)

Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Pope, Janet, et al.
Publicado: (2020)

A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease
por: Tardella, Marika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9aok1pm0133alklnbt9sp2ba6k